Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Diagn Microbiol Infect Dis ; 103(3): 115715, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35598409

RESUMO

Chlamydia (C.) abortus is an emerging zoonotic pathogen. Since data on its antimicrobial susceptibility are lacking, we aimed to determine minimal inhibitory (MIC) and minimal bactericidal concentrations (MBC) for azithromycin and doxycycline in HeLa-cells and primary human macrophages (M1). We also examined the MDM2-p53-inhibitor nutlin-3, an anti-infective imidazoline analog. Azithromycin and doxycycline demonstrated MICs and MBCs equal or below their peak serum concentrations (PSC) after standard dosing in both cell types. While doxycycline exhibited an MIC 64-fold and an MBC 4-fold below its PSC in HeLa-cells, the MIC of azithromycin was 4-fold below, the MBC equal to the PSC. However, azithromycin revealed lower MBCs in M1. The pharmacological advantage of azithromycin accumulation in phagocytes and their role as chlamydial reservoirs remain uncertain. However, our data suggest possible therapeutic advantages of doxycycline in epithelial cells and we provide first evidence for an anti-C. abortus effect of nutlin-3 in M1.


Assuntos
Antibacterianos , Infecções por Chlamydia , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Azitromicina/farmacologia , Chlamydia , Chlamydia trachomatis , Doxiciclina/farmacologia , Doxiciclina/uso terapêutico , Células Epiteliais , Humanos , Imidazóis , Macrófagos , Piperazinas , Proteínas Proto-Oncogênicas c-mdm2/farmacologia , Proteína Supressora de Tumor p53/farmacologia , Proteína Supressora de Tumor p53/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA